Genesco, Inc. (GCO) Reports Q1 Beat; Boosts FY13 Outlook
Tweet
Share
E-mailGet Alerts GCO Hot Sheet
Price: $35.16 --0%
Revenue Growth %: -3.2%
Financial Fact:
Net (loss) earnings: 1.3
Today's EPS Names:
VAXX, NMRD, EGRX, More
Revenue Growth %: -3.2%
Financial Fact:
Net (loss) earnings: 1.3
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Genesco, Inc. (NYSE: GCO) reported Q1 EPS of $0.98, vs. the analyst estimate of $0.74. Revenue for the quarter came in at $600 million versus the consensus estimate of $577.11 million.
Sees FY2013 EPS of $4.70-$4.82, versus prior guidance of $4.58-$4.70 and the consensus of $4.69.
For earnings history and earnings-related data on Genesco, Inc. (GCO) click here.
Sees FY2013 EPS of $4.70-$4.82, versus prior guidance of $4.58-$4.70 and the consensus of $4.69.
For earnings history and earnings-related data on Genesco, Inc. (GCO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Ascendis Pharma (ASND) Tops Q2 EPS by 132c
- Madison Square Garden Sports Corp. (MSGS) Tops Q4 EPS by 62c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
